Literature DB >> 20357826

EVI1 overexpression in distinct subtypes of pediatric acute myeloid leukemia.

B V Balgobind1, S Lugthart, I H Hollink, S T J C M Arentsen-Peters, E R van Wering, S S N de Graaf, D Reinhardt, U Creutzig, G J L Kaspers, E S J M de Bont, J Stary, J Trka, M Zimmermann, H B Beverloo, R Pieters, R Delwel, C M Zwaan, M M van den Heuvel-Eibrink.   

Abstract

Overexpression of the ecotropic virus integration-1 (EVI1) gene (EVI1+), localized at chromosome 3q26, is associated with adverse outcome in adult acute myeloid leukemia (AML). In pediatric AML, 3q26 abnormalities are rare, and the role of EVI1 is unknown. We studied 228 pediatric AML samples for EVI1+ using gene expression profiling and RQ-PCR. EVI1+ was found in 20/213 (9%) of children with de novo AML, and in 4/8 with secondary AML. It was predominantly found in MLL-rearranged AML (13/47), monosomy 7 (2/3), or FAB M6/7 (6/10), and mutually exclusive with core-binding factor AML, t(15;17), and NPM1 mutations. Fluorescent in situ hybridization (FISH) was performed to detect cryptic 3q26 abnormalities. However, none of the EVI1+ patients harbored structural 3q26 alterations. Although significant differences in 4 years pEFS for EVI1+ and EVI1- pediatric AML were observed (28%+/-11 vs 44%+/-4, P=0.04), multivariate analysis did not identify EVI1+ as an independent prognostic factor. We conclude that EVI1+ can be found in approximately 10% of pediatric AML. Although EVI1+ was not an independent prognostic factor, it was predominantly found in subtypes of pediatric AML that are related with an intermediate to unfavorable prognosis. Further research should explain the role of EVI1+ in disease biology in these cases. Remarkably, no 3q26 abnormalities were identified in EVI1+ pediatric AML.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20357826     DOI: 10.1038/leu.2010.47

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  27 in total

1.  Overexpression of Evi-1 oncoprotein represses TGF-β signaling in colorectal cancer.

Authors:  Xiyun Deng; Yanna Cao; Yan Liu; Fazhi Li; Kamalanathan Sambandam; Srinivasan Rajaraman; Archibald S Perkins; Alan P Fields; Mark R Hellmich; Courtney M Townsend; E Aubrey Thompson; Tien C Ko
Journal:  Mol Carcinog       Date:  2011-12-07       Impact factor: 4.784

2.  Evaluation of gene expression signatures predictive of cytogenetic and molecular subtypes of pediatric acute myeloid leukemia.

Authors:  Brian V Balgobind; Marry M Van den Heuvel-Eibrink; Renee X De Menezes; Dirk Reinhardt; Iris H I M Hollink; Susan T J C M Arentsen-Peters; Elisabeth R van Wering; Gertjan J L Kaspers; Jacqueline Cloos; Evelien S J M de Bont; Jean-Michel Cayuela; Andre Baruchel; Claus Meyer; Rolf Marschalek; Jan Trka; Jan Stary; H Berna Beverloo; Rob Pieters; C Michel Zwaan; Monique L den Boer
Journal:  Haematologica       Date:  2010-10-22       Impact factor: 9.941

3.  High expression of EVI1 and MEL1 is a compelling poor prognostic marker of pediatric AML.

Authors:  A Jo; S Mitani; N Shiba; Y Hayashi; Y Hara; H Takahashi; I Tsukimoto; A Tawa; K Horibe; D Tomizawa; T Taga; S Adachi; T Yoshida; H Ichikawa
Journal:  Leukemia       Date:  2015-01-08       Impact factor: 11.528

4.  EVI1 overexpression is a poor prognostic factor in pediatric patients with mixed lineage leukemia-AF9 rearranged acute myeloid leukemia.

Authors:  Hidemasa Matsuo; Mio Kajihara; Daisuke Tomizawa; Tomoyuki Watanabe; Akiko Moriya Saito; Junichiro Fujimoto; Keizo Horibe; Kumi Kodama; Mayu Tokumasu; Hiroshi Itoh; Hideki Nakayama; Akitoshi Kinoshita; Takashi Taga; Akio Tawa; Tomohiko Taki; Norio Shiba; Kentaro Ohki; Yasuhide Hayashi; Yuka Yamashita; Akira Shimada; Shiro Tanaka; Souichi Adachi
Journal:  Haematologica       Date:  2014-07-11       Impact factor: 9.941

Review 5.  Opportunities for immunotherapy in childhood acute myeloid leukemia.

Authors:  Adam J Lamble; Sarah K Tasian
Journal:  Blood Adv       Date:  2019-11-26

6.  High EVI1 expression is associated with MLL rearrangements and predicts decreased survival in paediatric acute myeloid leukaemia: a report from the children's oncology group.

Authors:  Phoenix A Ho; Todd A Alonzo; Robert B Gerbing; Jessica A Pollard; Betsy Hirsch; Susana C Raimondi; Todd Cooper; Alan S Gamis; Soheil Meshinchi
Journal:  Br J Haematol       Date:  2013-07-04       Impact factor: 6.998

Review 7.  Opportunities for immunotherapy in childhood acute myeloid leukemia.

Authors:  Adam J Lamble; Sarah K Tasian
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2019-12-06

8.  EVI1 is critical for the pathogenesis of a subset of MLL-AF9-rearranged AMLs.

Authors:  Eric M J Bindels; Marije Havermans; Sanne Lugthart; Claudia Erpelinck; Elizabeth Wocjtowicz; Andrei V Krivtsov; Elwin Rombouts; Scott A Armstrong; Erdogan Taskesen; Jurgen R Haanstra; H Berna Beverloo; Hartmut Döhner; Wendy A Hudson; John H Kersey; Ruud Delwel; Ashish R Kumar
Journal:  Blood       Date:  2012-05-02       Impact factor: 22.113

9.  Prognostic significance of additional cytogenetic aberrations in 733 de novo pediatric 11q23/MLL-rearranged AML patients: results of an international study.

Authors:  Eva A Coenen; Susana C Raimondi; Jochen Harbott; Martin Zimmermann; Todd A Alonzo; Anne Auvrignon; H Berna Beverloo; Myron Chang; Ursula Creutzig; Michael N Dworzak; Erik Forestier; Brenda Gibson; Henrik Hasle; Christine J Harrison; Nyla A Heerema; Gertjan J L Kaspers; Anna Leszl; Nathalia Litvinko; Luca Lo Nigro; Akira Morimoto; Christine Perot; Dirk Reinhardt; Jeffrey E Rubnitz; Franklin O Smith; Jan Stary; Irina Stasevich; Sabine Strehl; Takashi Taga; Daisuke Tomizawa; David Webb; Zuzana Zemanova; Rob Pieters; C Michel Zwaan; Marry M van den Heuvel-Eibrink
Journal:  Blood       Date:  2011-05-06       Impact factor: 22.113

10.  Myeloid leukemia with high EVI1 expression is sensitive to 5-aza-2'-deoxycytidine by targeting miR-9.

Authors:  F Li; W He; R Geng; X Xie
Journal:  Clin Transl Oncol       Date:  2019-05-03       Impact factor: 3.405

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.